L
Liliane Demange
Researcher at Curie Institute
Publications - 11
Citations - 1401
Liliane Demange is an academic researcher from Curie Institute. The author has contributed to research in topics: Germline mutation & Point mutation. The author has an hindex of 10, co-authored 11 publications receiving 1300 citations.
Papers
More filters
Journal ArticleDOI
Mutation Spectrum and Genotype-Phenotype Analyses in Cowden Disease and Bannayan-Zonana Syndrome, Two Hamartoma Syndromes With Germline PTEN Mutation
Deborah J. Marsh,Valérie Coulon,Kathryn L. Lunetta,Philippe Rocca-Serra,Patricia L. M. Dahia,Zimu Zheng,Danny Liaw,Stacey Caron,Bernadette Duboué,Albert Y. Lin,Anne Louise Richardson,Jean Marie Bonnetblanc,Jean Marie Bressieux,Agnés Cabarrot-Moreau,Agnès Chompret,Liliane Demange,Rosalind A. Eeles,Alan M. Yahanda,Eric R. Fearon,Jean Pierre Fricker,Robert J. Gorlin,Shirley Hodgson,Susan Huson,Didier Lacombe,Frédéric Leprat,Sylvie Odent,Claude Toulouse,Olufunmilayo I. Olopade,Hagay Sobol,Sigrid Tishler,C. Geoffrey Woods,Bruce G. Robinson,H. Christian Weber,Ramon Parsons,Monica Peacocke,Michel Longy,Charis Eng,Charis Eng +37 more
TL;DR: There appeared to be an interdependent association between mutations upstream and within the PTPase core motif, the core motif containing the majority of missense mutations, and the involvement of all major organ systems (central nervous system, thyroid, breast, skin and gastrointestinal tract).
Journal ArticleDOI
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma
Corine Bertolotto,Fabienne Lesueur,Sandy Giuliano,Thomas Strub,Mahaut de Lichy,Karine Bille,Philippe Dessen,Benoit d’Hayer,Hamida Mohamdi,Audrey Remenieras,Eve Maubec,Arnaud de la Fouchardière,Vincent Molinié,Pierre Vabres,Stéphane Dalle,N. Poulalhon,Tanguy Martin-Denavit,Luc Thomas,Pascale Andry-Benzaquen,Nicolas Dupin,F. Boitier,Annick Rossi,Jean-Luc Perrot,Bruno Labeille,Caroline Robert,Bernard Escudier,Olivier Caron,Laurence Brugières,Simon Saule,Betty Gardie,Sophie Gad,Stéphane Richard,Jérôme Couturier,Bin Tean Teh,Paola Ghiorzo,Lorenza Pastorino,Susana Puig,Celia Badenas,Håkan Olsson,Christian Ingvar,Etienne Rouleau,Rosette Lidereau,Philippe Bahadoran,Philippe Vielh,Eve Corda,Hélène Blanché,Diana Zelenika,Pilar Galan,François Aubin,Bertrand Bachollet,Celine Becuwe,Pascaline Berthet,Yves-Jean Bignon,Valérie Bonadona,Jean -Louis Bonafe,Marie -Noelle Bonnet-Dupeyron,Frédéric Cambazard,Jacqueline Chevrant-Breton,Isabelle Coupier,Sophie Dalac,Liliane Demange,Michel D'Incan,Catherine Dugast,Laurence Faivre,Lynda Vincent-Fetita,Marion Gauthier-Villars,Brigitte Gilbert,Florent Grange,Jean-Jacques Grob,Philippe Humbert,Nicolas Janin,Pascal Joly,Delphine Kerob,Christine Lasset,Dominique Leroux,Julien Levang,Jean -Marc Limacher,Cristina Bulai Livideanu,Michel Longy,Alain Lortholary,Dominique Stoppa-Lyonnet,Sandrine Mansard,Ludovic Mansuy,Karine Marrou,Christine Mateus,Christine Maugard,Nicolas Meyer,Catherine Noguès,Pierre Souteyrand,Laurence Venat-Bouvet,Hélène Zattara,Valérie Chaudru,Gilbert M. Lenoir,Mark Lathrop,Irwin Davidson,Marie-Françoise Avril,Florence Demenais,Robert Ballotti,Brigitte Bressac-de Paillerets +98 more
TL;DR: A germline missense substitution in MITF (Mi-E318K) is identified that occurred at a significantly higher frequency in genetically enriched patients affected with melanoma, RCC or both cancers, when compared with controls and provides insights into the link between SUMOylation, transcription and cancer.
Journal ArticleDOI
Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families.
Sophie Gad,Virginie Caux-Moncoutier,Sabine Pagès-Berhouet,Marion Gauthier-Villars,Isabelle Coupier,Pascal Pujol,Marc Frenay,Brigitte Gilbert,Christine Maugard,Yves-Jean Bignon,Annie Chevrier,Annick Rossi,Jean-Pierre Fricker,Tan Dat Nguyen,Liliane Demange,Alain Aurias,Aaron Bensimon,Dominique Stoppa-Lyonnet +17 more
TL;DR: BRCA1 large rearrangements accounted for 3.3% (4/120) of breast-ovarian cancer cases and 9.5% of the BRCA 1 gene mutation spectrum, suggesting that their screening is an important step that should be now systematically included in genetic testing surveys.
Journal ArticleDOI
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results
Jacques Rouëssé,Brigitte De La Lande,Frédérique Bertheault-Cvitkovic,Daniel Serin,Yvon Graic,Martin Combe,Bernard Leduc,Virginie Lucas,Liliane Demange,Tan Dat Nguyen,Daniel Castèra,Claude Krzisch,Richard Villet,Emmanuelle Mouret-Fourme,J.-R. Garbay,Catherine Noguès +15 more
TL;DR: Concomitant radiotherapy with adjuvant fluorouracil, mitoxantrone, and cyclophosphamide has significantly better locoregional control in node-positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity.
Journal ArticleDOI
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Olga M. Sinilnikova,A C Antoniou,Jacques Simard,Sue Healey,Mélanie Léoné,Daniel Sinnett,Amanda B. Spurdle,Jonathan Beesley,Xiaoqing Chen,kConFab,Mark H. Greene,Jennifer T. Loud,Flavio Lejbkowicz,Gad Rennert,Sara Dishon,Irene L. Andrulis,Ocgn,Susan M. Domchek,Katherine L. Nathanson,Siranoush Manoukian,Paolo Radice,Irene Konstantopoulou,Ignacio Blanco,A L Laborde,Mercedes Durán,Ana Osorio,Javier Benitez,U Hamann,Frans B. L. Hogervorst,T. A. M. van Os,Hans J. J. P. Gille,Hebon,Susan Peock,M. Cook,Craig Luccarini,D. G. Evans,Fiona Lalloo,Rosalind A. Eeles,Gabriella Pichert,Rosemarie Davidson,Trevor Cole,Jacqueline Cook,Joan Paterson,Carole Brewer,Embrace,David J. Hughes,Isabelle Coupier,S. Giraud,Florence Coulet,Chrystelle Colas,Florent Soubrier,Etienne Rouleau,Ivan Bièche,Rosette Lidereau,Liliane Demange,Catherine Noguès,Henry T. Lynch,Gemo,Rita K. Schmutzler,Beatrix Versmold,Christoph Engel,Alfons Meindl,Norbert Arnold,Christian Sutter,Helmut Deissler,Dieter Schaefer,Ursula G. Froster,Gc-Hboc,Kristiina Aittomäki,Heli Nevanlinna,Lesley McGuffog,Douglas F. Easton,Georgia Chenevix-Trench,Dominique Stoppa-Lyonnet +73 more
TL;DR: There was no evidence that TP53 Arg72Pro or MDM2 309T>G, either singly or in combination, influence breast cancer risk in BRCA1 or BRCa2 mutation carriers.